The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL

• DOI: 10.18632/oncotarget.15711
• Publication Date: 2017-02-27T00:42:15Z
• Authors: Sanghoon Lee; Wen Luo; Tishi Shah; Changhong Yin; Timmy O’Connell; Tae-Hoon Chung; Sherrie L. Perkins; Rodney R. Miles; Janet Ayello; Erin Morris; Lauren Harrison; Carmella van de Ven; Mitchell S. Cairo
• Keywords: Chemoimmunotherapy

// Sanghoon Lee 1, 2, * , Wen Luo Tishi Shah 1 Changhong Yin Timmy O'Connell 3 Tae-Hoon Chung 4 Sherrie L. Perkins 5 Rodney R. Miles Janet Ayello Erin Morris Lauren Harrison Carmella van de Ven Mitchell S. Cairo 3, 6, 7 Departments of Pediatrics, New York Medical College, Valhalla, York, USA 2 Cell Biology and Anatomy, Microbiology Immunology, Cancer Science Institute Singapore, National University Singapore Department Pathology ARUP Laboratories, Utah, Salt Lake City, 6 Pathology, Medicine, First primary co-authors Correspondence to: Cairo, email: [e-mail] Keywords: DLEU1, tumor suppressor, chemoimmunotherapy, genome editing, B-NHL Received: November 17, 2016 Accepted: February 12, 2017 Published: 24, ABSTRACT Following a multivariant analysis we demonstrated that children adolescents with Burkitt lymphoma (BL) 13q14.3 deletion have significant decrease in event free survival (EFS) despite identical short intensive multi-agent chemotherapy. However, how this the region is associated EFS BL largely unknown. The gene Deleted Lymphocytic Leukemia ( DLEU1 ) located 13q14.3. Here, report expression implicated regulation programmed cell death, proliferation, apoptotic genes transcription activator-like effector nuclease (TALEN)s-induced knockdown overexpressing lines. Furthermore, NSG mice xenografted cells had significantly shortened p < 0.05 0.005), whereas those improved 0.0001), following treatment rituximab and/or cyclophosphamide. These data suggest may part function as suppressor confer chemoimmunotherapy resistance BL.